What Happened

Werewolf Therapeutics closed Q2 2026 with a $21M asset sale to Jazz Pharmaceuticals, resulting in net income of $3.7M vs. a $18M loss in Q2 2025. The company repaid its K2 HealthVentures debt and retains $22M cash, projecting runway into Q2 2027.

Who Is Affected

Jazz Pharmaceuticals gains full rights to the JZP898 program. Piper Sandler leads Werewolf's strategic review, positioning it as a potential M&A or financing advisor. Vendors serving biotech clinical trials (WTX-124, WTX-330) may see renewed engagement.

Market Impact

• Biotech lenders: K2 HealthVentures loan fully repaid
• Investment banks: Piper Sandler managing strategic alternatives
• Clinical vendors: Pending updates on WTX-124/330 trials

What to Watch

Werewolf will disclose strategic alternatives (M&A, partnerships, financing) and clinical trial data in H2 2026. Monitor Jazz Pharmaceuticals' integration of JZP898 and institutional trading activity ($HOWL).

Related coverage

• Elucid Raises $55M Series D to Expand AI Heart Care Platform
• Moleculin Biotech updates Annamycin data, prices stock offering at $0.75
• Saudi Biotech Fund IB Ventures Launches With $50 Million Raise
• Vaxart Updates BARDA Funding Award for COVID-19 Oral Pill Vaccine Trial